|
|
|
|
|
Sponsored by: |
Isis Pharmaceuticals |
Information provided by: | NIH AIDS Clinical Trials Information Service |
ClinicalTrials.gov Identifier: | NCT00002187 |
The purpose of this study is to compare the safety and effectiveness of two dosage schedules for ISIS 2922 in the treatment of advanced cytomegalovirus (CMV) retinitis
Condition | Intervention |
Cytomegalovirus Retinitis HIV Infections |
Drug: Fomivirsen sodium |
MedlinePlus related topics: | AIDS Cytomegalovirus Infections |
ChemIDplus related topics: | Fomivirsen sodium Fomivirsen |
Study Type: | Interventional |
Study Design: | Treatment, Parallel Assignment, Safety Study |
Official Title: | A Randomized Comparison of Two Dosage Schedules of Intravitreal ISIS 2922 for Patients With Advanced Cytomegalovirus Retinitis |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Concurrent Medication:
Allowed:
Patients must have:
Prior Medication:
Required:
Allowed:
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms and conditions are excluded:
Patients with the following prior conditions are excluded:
History of syphilis.
1. Systemic anti-CMV therapies other than oral ganciclovir.
United States, California | |||||
Dr Jacob Lalezari | |||||
San Francisco, California, United States, 94115 | |||||
Community Eye Med Group | |||||
Pasadena, California, United States, 911052536 | |||||
Retina - Vitreous Associates Med Group | |||||
Los Angeles, California, United States, 90017 | |||||
Univ of California San Francisco / SF Gen Hosp | |||||
San Francisco, California, United States, 94110 | |||||
United States, District of Columbia | |||||
Dr Alan Palestine | |||||
Washington, District of Columbia, United States, 20006 | |||||
United States, Florida | |||||
Dr Julio Perez | |||||
Fort Lauderdale, Florida, United States, 33060 | |||||
United States, Georgia | |||||
Georgia Retina | |||||
Atlanta, Georgia, United States, 30327 | |||||
United States, Illinois | |||||
Univ of Illinois | |||||
Chicago, Illinois, United States, 60612 | |||||
Chicago Ctr for Clinical Research | |||||
Chicago, Illinois, United States, 60610 | |||||
United States, Indiana | |||||
Indiana Univ Med Ctr | |||||
Indianapolis, Indiana, United States, 46202 | |||||
United States, New York | |||||
New York Univ Med Ctr | |||||
New York, New York, United States, 10016 | |||||
Vitreo - Retinal Consultants | |||||
New York, New York, United States, 10028 | |||||
United States, North Carolina | |||||
Charlotte Eye Ear Nose & Throat Association | |||||
Charlotte, North Carolina, United States, 28204 | |||||
Duke Univ | |||||
Durham, North Carolina, United States, 27710 | |||||
United States, Pennsylvania | |||||
Hahnemann Univ Hosp | |||||
Philadelphia, Pennsylvania, United States, 191021192 | |||||
United States, Texas | |||||
Baylor College of Medicine | |||||
Houston, Texas, United States, 77030 | |||||
United States, Washington | |||||
Novum Inc | |||||
Seattle, Washington, United States, 98104 |
Isis Pharmaceuticals |
Study ID Numbers: | 251D, ISIS 2922-CS9 |
First Received: | November 2, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00002187 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|
|